department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Turalio · pharmadog

pharmadog
drugs
Turalio

drug

patient view →

pexidartinib hydrochloride

Marketedupdated 2mo ago

by Daiichi Sankyo Co Ltd

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Turalio

generic

pexidartinib hydrochloride

indication

Tenosynovial Giant Cell Tumor

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 2, 2026

26 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

Jul 24, 2038formulationUS 10435404
Jul 24, 2038formulationUS 10435404
Jul 24, 2038formulationUS 10941142
Jul 24, 2038formulationUS 10941142
Jul 24, 2038method-of-use (U-2606)US 10961240
Jul 24, 2038method-of-use (U-2606)US 10961240
May 5, 2036method-of-use (U-2606)US 10189833
May 5, 2036method-of-use (U-2606)US 10189833
May 5, 2036compositionUS 10730876
May 5, 2036compositionUS 10730876
May 5, 2036compositionUS 9802932
May 5, 2036compositionUS 9802932
Jun 8, 2033method-of-use (U-2606)US 9358235
Jun 8, 2033method-of-use (U-2606)US 9358235
May 4, 2033compositionUS 7893075
May 4, 2033compositionUS 7893075
Apr 19, 2028method-of-use (U-2606)US 84611691.8y
Apr 19, 2028method-of-use (U-2606)US 84611691.8y
Nov 21, 2027compositionUS 84047001.4y
Nov 21, 2027compositionUS 84047001.4y
Nov 21, 2027compositionUS 87227021.4y
Nov 21, 2027compositionUS 87227021.4y
Nov 21, 2027compositionUS 91692501.4y
Nov 21, 2027compositionUS 91692501.4y

FDA exclusivities (2)

Aug 2, 2026ODE-250Orphan Drug (7y)26d
Aug 2, 2026ODE*ODE*26d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying pexidartinib hydrochloride

—A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatmentrecruitingn=30